AcceGen

  2019-nCoV  (also called   severe acute respiratory syndrome coronavirus 2 , or   SARS-CoV-2 ) is a strain of coronavirus that causes the infectious disease known as   COVID-19 .   AcceGen  is committed to supporting COVID-19 research by providing biotech organizations with pulmonary alveolar epithelial cells (PAEpiC and HPAEpiC-II), bronchial epithelial cells, and other diagnostic and therapeutic tools.     At the present time,  2019-nCoV  is believed to have emerged in December 2019 in Wuhan, Hubei Province, China, and, like approximately 60% of infectious diseases, is assumed (generally) to be of  zoonotic origin . The first confirmed cases of COVID-19 transpired in Finland, India, and the Philippines, all in persons who had recently traveled to Wuhan.   This novel coronavirus, which is believed to spread person to person chiefly by secretions from the nose and mouth, usually produces fever and cough, and often fatigue and shortness of breath, in infected individuals. COVID-19 is r

  The interaction of the host-microbiome balance is essential for maintaining   homeostasis  in the gastrointestinal tract[1].   Intestinal epithelial cells (IECs)  provide the front line of defense by building a barrier against pathogens and symbiotic microorganisms[2].   The Structure of Intestinal Epithelial Cells Intestinal epithelial cells are found in  crypts . IECs are mainly composed of transit-amplifying (TA) cells,  Paneth cells , Microfold cells (or M cells),  Enteroendocrine cells  and  Tuft cells [3]. These cells work together to maintain intestinal homeostasis. However, the loss of intestinal epithelial cells may damage intestinal stem cells (ISC) which makes the intestine unable to repair itself and leading to intestinal diseases[4].     Fig 1.  Schematic diagram of epithelial cell types and signaling pathways in crypts[3].   Intestinal epithelial cells (IECs) may contribute to local immunomodulatory. Therefore, successfully isolated and correctly cultured intestinal epi